Detecting T‐cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab
Journal of the European Academy of Dermatology and Venereology · 2024
DOI: 10.1111/jdv.20053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Hyungdon Kook und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Medical Center, Seoul, Korea. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background
Trials and real‐life studies demonstrated clinically meaningful improvements of disease activity in the majority of patients with moderate to severe atopic dermatitis (AD) treated with the anti‐IL‐4RA‐antibody dupilumab. However, misdiagnosis or confounding skin diseases in particular cutaneous T‐cell lymphoma (CTCL) may lead to inadequate response.
Objective
To investigate the clinical and pathological features of patients with AD who showed insufficient response to dupilumab.
Methods
We reviewed the medical records of 371 patients treated with dupilumab for severe AD. Insufficient response was defined as failure to achieve an improvement of the eczema area severity index (EASI) of at least 50% (EASI‐50) at Week 16 and of 75% (EASI‐75) at Week 52. Among 46 patients with insufficient response, 35 patients consented to a re‐evaluation including a full physical exam, biopsies and laboratory assessments including immunohistochemistry and T‐cell receptor gene rearrangement analysis to differentiate CTCL.
Results
Of the 371 patients treated with dupilumab, 46 (12.3%) patients showed insufficient response to dupilumab. Of these, 35 underwent further evaluation, and 19 (54.2% of inadequate responders) were finally diagnosed with mycosis fungoides (MF). In these patients, transition to or addition of conventional MF treatment led to clinical improvements.
Conclusions
Insufficient response to dupilumab treatment may help uncover early MF on an existing AD background.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Medical Center, Seoul, Korea.
- Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea.
- Department of Dermatology, College of Medicine, Soonchunhyang University, Seoul, Korea.
- Genome Medicine Institute, College of Medicine, Seoul National University, Seoul, Korea.
- Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.
ORCID-Profile: Hyungdon Kook, So Yun Park, Narang Hong, Mi Youn Park, Hyun Je Kim, Stephan Weidinger, Jiyoung Ahn
Zitieren
APA
Kook, H., Gwag, H. E., Park, S. Y., Hong, N., Lee, J. H., Jung, H. J., Park, M. Y., Choi, Y. S., Kim, H. J., Weidinger, S., & Ahn, J. (2024). Detecting T‐cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20053
Vancouver
Kook H, Gwag HE, Park SY, Hong N, Lee JH, Jung HJ, et al. Detecting T‐cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.20053
BibTeX
@article{Kook2024,
author = {Kook, Hyungdon and Gwag, Ho Eun and Park, So Yun and Hong, Narang and Lee, Jung-Ho and Jung, Hye Jung and Park, Mi Youn and Choi, Yu Sung and Kim, Hyun Je and Weidinger, Stephan and Ahn, Jiyoung},
title = {Detecting T‐cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
doi = {10.1111/jdv.20053}
}
EUVIMED